The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Differences between Japan and rest of world (ROW) in disease presentation and outcome of previously treated adult t-cell leukemia-lymphoma (ATL) using therapy with a monoclonal antibody to CCR4, mogamulizumab (moga).
 
Adrienne Alise Phillips
Honoraria - Celgene; Genentech; Takeda
Consulting or Advisory Role - Takeda
Speakers' Bureau - Celgene; Takeda
Research Funding - Kyowa Hakko Kirin
 
Steven M. Horwitz
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Millennium; Seagen; Spectrum Pharmaceuticals
Research Funding - Celgene; Infinity Pharmaceuticals; Kyowa Hakko Kirin; Millennium; Seagen; Spectrum Pharmaceuticals
Travel, Accommodations, Expenses - ADC Therapeutics; Janssen; RAND Corporation
 
Graham P. Taylor
Research Funding - Kyowa Hakko Kirin (Inst)
Patents, Royalties, Other Intellectual Property - Imperial College London
 
Jeffrey S. Humphrey
Employment - AstraZeneca (I); CytomX Therapeutics (I); Jounce Therapeutics (I); Kyowa Hakko Kirin; Lilly (I)
Leadership - CytomX Therapeutics
Stock and Other Ownership Interests - CytomX Therapeutics
Honoraria - Syndax
Consulting or Advisory Role - Syndax
 
Kensei Tobinai
Honoraria - Eisai; Mundipharma; Spectrum Pharmaceuticals; Takeda; Zenyaku Kogyo
Research Funding - Abbvie (Inst); Celgene (Inst); Chugai Pharma (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Mundipharma (Inst); Ono Pharmaceutical (Inst); SERVIER (Inst); Takeda (Inst)
 
Takashi Ishida
Honoraria - Kyowa Hakko Kirin
Research Funding - Bayer (Inst); Celgene (Inst); Kyowa Hakko Kirin (Inst)
 
Ryuzo Ueda
Leadership - TERUMO
Honoraria - Chugai Pharma; Kyowa Hakko Kirin; Ono Pharmaceutical
Consulting or Advisory Role - Mundipharma; Ono Pharmaceutical
Research Funding - Chugai Pharma (Inst); Kyowa Hakko Kirin (Inst); Medical & Biological Laboratories (Inst); Rikaken (Inst)